A Peek at ResMed's Future Earnings
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) is set to release its quarterly earnings report on October 24, 2024, with analysts estimating an EPS of $2.04. Investors are keen on not just an earnings beat but also positive future guidance. ResMed's past performance shows a pattern of share price increases following earnings beats. Analysts have a Neutral consensus on ResMed with a slight potential downside in price target. ResMed shows strong revenue growth and profitability metrics compared to peers.
October 23, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed is expected to report its quarterly earnings with an estimated EPS of $2.04. Investors are looking for not only an earnings beat but also positive guidance. Past earnings beats have led to share price increases. Analysts have a Neutral rating with a slight downside in price target.
ResMed's upcoming earnings report is highly anticipated, with analysts expecting an EPS of $2.04. The company's history of share price increases following earnings beats suggests a positive short-term impact if they exceed expectations. Additionally, positive guidance could further boost investor sentiment. The Neutral analyst rating and slight downside in price target indicate moderate expectations, but the potential for a positive surprise remains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100